PT  - JOURNAL ARTICLE
AU  - Andrew J Swift
AU  - Frederick Wilson
AU  - Marcella Cogliano
AU  - Lindsay Kendall
AU  - Faisal Alandejani
AU  - Samer Alabed
AU  - Paul Hughes
AU  - Yousef Shahin
AU  - Laura Saunders
AU  - Charlotte Oram
AU  - David Capener
AU  - Alex Rothman
AU  - Pankaj Garg
AU  - Christopher Johns
AU  - Matthew Austin
AU  - Alistair Macdonald
AU  - Jo Pickworth
AU  - Peter Hickey
AU  - Robin Condliffe
AU  - Anthony Cahn
AU  - Allan Lawrie
AU  - Jim M Wild
AU  - David G Kiely
TI  - Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study
AID  - 10.1136/thoraxjnl-2020-216078
DP  - 2021 Oct 01
TA  - Thorax
PG  - 1032--1035
VI  - 76
IP  - 10
4099  - http://thorax.bmj.com/content/76/10/1032.short
4100  - http://thorax.bmj.com/content/76/10/1032.full
SO  - Thorax2021 Oct 01; 76
AB  - End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test–retest repeatability was assessed using the intraclass correlation coefficient and treatment effect size using Cohen’s d statistic. Intraclass correlation coefficients demonstrated excellent repeatability for MRI, 6 min walk test and log to base 10 N-terminal pro-brain natriuretic peptide (log10NT-proBNP). The treatment effect size for MRI-derived right ventricular ejection fraction was large (Cohen’s d 0.81), whereas the effect size for the 6 min walk test (Cohen’s d 0.22) and log10NT-proBNP (Cohen’s d 0.20) were fair. This study supports further evaluation of MRI as a non-invasive end point for clinical assessment and PAH therapy trials.Trial registration number NCT03841344.